Prof. Thomas Insel
MindStrong Health, EUA
Ponència | Pot la tecnologia desentranyar la complexitat dels trastorns mentals? |
Data | Dijous, 19 d'Abril 2018 |
Hora | 18:45 a 19:30 |
Taula rodona | Models per explicar la complexitat |
BIOGRAFIA
Thomas R. lnsel, M.D., a psychiatrist and neuroscientist, is a co-founder and President of Mindstrong Health. From 2002-2015, Dr. Insel served as Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health (NIH) committed to research on mental disorders. Prior to serving as NIMH Director, Dr. lnsel was Professor of Psychiatry at Emory University where he was founding director of the Center for Behavioral Neuroscience in Atlanta. Most recently (2015 – 2017), he led the Mental Health Team at Verily (formerly Google Life Sciences) in South San Francisco, CA. Dr. Insel is a member of the National Academy of Medicine and has received numerous national and international awards including honorary degrees in the U.S. and Europe.
RESUM
Digital technologies are being developed to address a broad range of health challenges. Mental health challenges may seem particularly suited for a digital solution. As mental disorders are experienced as behavioral or cognitive problems, digital phenotyping based on smartphone sensor data, keyboard performance, and voice/speech is especially promising for detecting and diagnosing anxiety, mood, or psychotic disorders. In contrast to traditional assessments which are subjective, episodic, and clinic-based; digital phenotyping can deliver objective, continuous, and ecological assessments of behavior. Because the assessment is passive and the technology is ubiquitous, there is understandable enthusiasm about this new approach to measuring behavior and cognition. But will better measurement result in better outcomes? We do not yet have the evidence to answer this question. This lecture will explore the promise and problems of digital phenotyping, arguing that better measurement will be fundamental to better management of mental disorders and describing the studies necessary to prove the clinical value and ensure the public trust for this new technology.
REFERÈNCIES
[web] Insel TR (2018).
Join the disruptors of health science, Nature. 2017 Nov 1;551(7678):23-26. doi: 10.1038/551023a.
[web] Insel TR (2018). Technology as a Tool for Mental Disorders-Reply, JAMA. 2018 Feb 6;319(5):504. doi: 10.1001/jama.2017.20353.
[web] Insel TR (2017). Digital Phenotyping: Technology for a New Science of Behavior, JAMA. 2017 Oct 3;318(13):1215-1216. doi: 10.1001/jama.2017.11295.
[web] Insel TR (2018). Technology as a Tool for Mental Disorders-Reply, JAMA. 2018 Feb 6;319(5):504. doi: 10.1001/jama.2017.20353.
[web] Insel TR (2017). Digital Phenotyping: Technology for a New Science of Behavior, JAMA. 2017 Oct 3;318(13):1215-1216. doi: 10.1001/jama.2017.11295.
Tornar al Programa 2018